x

INTERNATIONAL ISOTOPES INC (OTC:INIS)

Health Care/Life Sciences • Pharmaceuticals
CIK 1038277
Company

International Isotopes, Inc. engages in the manufacture of nuclear medicine calibration and reference standards cobalt tele therapy sources, as well as radioisotopes and radiochemical for medical research and clinical devices. It operates through the following segments: Radiochemical Products, Cobalt Products, Nuclear Medicine Standards, Fluorine Products, and Radiological Services. The Radiochemical Products segment includes production and distribution of various isotopically pure radio chemicals for medical, industrial, or research applications. The Cobalt Products segment includes management of a cobalt irradiation contract, fabrication of cobalt capsules for tele therapy or irradiation devices, and recycling of expended cobalt sources. The Nuclear Medicine Standards segment consists of the manufacture of sources and standards associated with Single Photon Emission Computed Tomography imaging, patient positioning, and calibration or operational testing of dose measuring equipment for the nuclear pharmacy industry. The Fluorine Products segment is involved in the production of small-scale qualification samples of high purity fluoride gas for various industrial applications. The Radiological Services Segment concerns a wide array of miscellaneous services that consists of gemstone processing and field services that include source installation, removal, and radiation device decommissioning. The company was founded in November 1995 and is headquartered in Idaho Falls, ID.

Address
4137 Commerce Circle
Idaho Falls, Idaho 83401
Employees
33
Stock Info
Close
$0.0436
Day Range
0.0440 - 0.0470
52 Week Range
0.0310 - 0.0950
Average volume
33.61K
Short Interest
N/A (N/A)
% of Float Shorted
N/A
Market Cap
$22.66M
Revenue
$11.18M
Net Income
$303.24K
2020 Sales Growth
N/A
Rev. per Employee
$371.84K
P/E Ratio
N/A
EPS
$-0.0017
Yield
N/A
Dividend
N/A
Ex-Dividend Date
N/A
Key Executives
Board Of Directors
President, Chief Executive Officer & Director
Shahe Bagerdjian
Director
Steve T Laflin
Chairman
Christopher G Grosso
Independent Director
Robert W Atcher PhD, MBA
SEC filings
DateFormEvent
22 Nov, 2024 4
22 Nov, 2024 4
18 Nov, 2024 4
12 Nov, 2024 10-Q
2 Oct, 2024 8-K
20 Sep, 2024 4
17 Sep, 2024 4
14 Aug, 2024 10-Q
16 Jul, 2024 8-K
18 Jun, 2024 4
18 Jun, 2024 4
21 May, 2024 DEF 14A
15 May, 2024 10-Q
29 Apr, 2024 DEF 14A
29 Apr, 2024 SC 13G/A
29 Mar, 2024 10-K
6 Mar, 2024 4
8 Feb, 2024 8-K
15 Dec, 2023 4
15 Dec, 2023 4
13 Nov, 2023 10-Q
7 Sep, 2023 4
29 Aug, 2023 4
11 Aug, 2023 10-Q
18 Jul, 2023 8-K CEO Change
24 May, 2023 DEF 14A
24 May, 2023 DEFA14A
15 May, 2023 10-Q
12 May, 2023 3
12 May, 2023 4
10 May, 2023 8-K
3 May, 2023 10-K/A
1 May, 2023 SC 13G/A
1 May, 2023 4
6 Apr, 2023 10-K
31 Mar, 2023 NT 10-K
28 Feb, 2023 8-K
28 Dec, 2022 8-K
7 Dec, 2022 4
14 Nov, 2022 10-Q
15 Aug, 2022 10-Q
19 Jul, 2022 8-K
20 May, 2022 DEFA14A
16 May, 2022 10-Q
2 May, 2022 SC 13G/A
2 May, 2022 DEF 14A
31 Mar, 2022 10-K
23 Feb, 2022 4
23 Feb, 2022 4
23 Feb, 2022 4
23 Feb, 2022 4
22 Feb, 2022 8-K
16 Feb, 2022 8-K
12 Nov, 2021 10-Q
16 Aug, 2021 10-Q
14 Jul, 2021 8-K
17 May, 2021 10-Q
30 Apr, 2021 4
30 Apr, 2021 4
30 Apr, 2021 DEF 14A
30 Apr, 2021 4
30 Apr, 2021 SC 13G/A
30 Apr, 2021 4
30 Mar, 2021 10-K
9 Feb, 2021 S-8
Last update:2024-03-06 12:23:23.458293

Sign Up to Subscribe